| 邹 娟,冯梦菁,王文静,晁 瑶,郑转珍.维奈克拉联合阿扎胞苷对老年急性髓系白血病患者T淋巴细胞亚群的影响及其疗效的影响因素分析[J].,2024,(22):4389-4392 |
| 维奈克拉联合阿扎胞苷对老年急性髓系白血病患者T淋巴细胞亚群的影响及其疗效的影响因素分析 |
| Analysis of the Effect of Venetoclax Combined with Azacytidine on T Lymphocyte Subsets in Elderly Patients with Acute Myeloid Leukemia and the Influencing Factors of its Efficacy |
| 投稿时间：2024-05-24 修订日期：2024-06-18 |
| DOI：10.13241/j.cnki.pmb.2024.22.057 |
| 中文关键词: 维奈克拉 阿扎胞苷 老年 急性髓系白血病 T淋巴细胞亚群 疗效 影响因素 |
| 英文关键词: Venetoclax Azacytidine Elderly Acute myeloid leukemia T lymphocyte subsets Efficacy Influence factors |
| 基金项目:山西省自然科学基金项目（20181D121330） |
|
| 摘要点击次数: 57 |
| 全文下载次数: 46 |
| 中文摘要: |
| 摘要 目的：观察维奈克拉联合阿扎胞苷对老年急性髓系白血病（AML）患者T淋巴细胞亚群的影响，并分析疗效的影响因素。方法：238例老年AML患者根据治疗方案的不同分为对照组120例（接受阿扎胞苷治疗）和研究组118例（维奈克拉联合阿扎胞苷治疗）。对比两组疗效、T淋巴细胞亚群变化情况、不良反应发生率。多因素Logistic回归分析影响疗效不佳的因素。结果：与对照组相比，研究组治疗后临床总有效率更高，CD3+、CD4+、CD4+/CD8+更高，CD8+更低（P<0.05）。两组不良反应总发生率对比未见差异（P>0.05）。血小板计数（PLT）偏低、乳酸脱氢酶（LDH）偏高、查尔森合并症指数（CCI）评分偏高是疗效不佳的危险因素（P<0.05）。结论：维奈克拉联合阿扎胞苷能够有效提高老年AML患者的临床疗效，改善免疫功能。此外，老年AML患者的疗效还受到PLT、LDH、CCI评分的影响。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of venetoclax combined with azacytidine on T lymphocyte subsets in elderly patients with acute myeloid leukemia (AML), and to analyze the influencing factors of efficacy. Methods: 238 elderly AML patients were divided into control group (n=120, treated with azacitidine) and study group (n=118, treated with venetoclax combine with azacitidine) according to the different treatment options. The efficacy, changes of T lymphocyte subsets and incidence of adverse reactions were compared in two groups. The influencing factors that affect the poor efficacy were analyzed by multivariate logistic regression. Results: Compared with control group, the total clinical effective rate in study group after treatment was higher, CD3+, CD4+, CD4+/CD8+ were higher, and CD8+ was lower (P<0.05). There was no difference in the total incidence of adverse reactions between two groups (P>0.05). Low platelet count (PLT), high lactate dehydrogenase (LDH), and high Chalson comorbidities index (CCI) score were risk factors for poor efficacy (P<0.05). Conclusion: Vinecra combined with azacytidine can effectively improve the clinical efficacy and immune function of elderly AML patients. In addition, the efficacy of elderly AML patients is also affected by PLT, LDH, and CCI scores. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
